NCT07171034 - A Phase I Study of KLA318-2 Nanocrystal Injection | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2026

Conditions

Healthy Participants

Interventions

DRUG

KLA318-2 Nanocrystal Injection

Intravenous injection, single dose

DRUG

Celebrex Capsule

P.O., single dose

Trial Locations (1)

The first affiliated hospital of Shandong First Medical University (Shandong Provincial Qianfoshan Hospital), Jinan